Browsing Tag
Calquence
5 posts
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE…
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of…
FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of…